SCHEMBL359818

SCHEMBL359818

CCNC(=O)Oc1cc(N2CCOCC2)cnc1N

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 6/20 0.48
JAK1 P23458 6/20 0.48
TYK2 P29597 6/20 0.48
JAK3 P52333 5/20 0.48
AKT1 P31749 2/20 0.42
PIK3CA P42336 2/20 0.42
MTOR P42345 1/20 0.42
MAPK1 P28482 2/20 0.41
POLB P06746 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
FYN P06241 1/20 0.40
BMPR1B O00238 1/20 0.39
BMPR1A P36894 1/20 0.39
TGFBR1 P36897 1/20 0.39
ACVRL1 P37023 1/20 0.39
ACVR1 Q04771 1/20 0.39
MAPT P10636 2/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL360214 0.83 ALDH1A1 (0.46) MAPK1POLBL3MBTL1SMN1; SMN2MAPT
SCHEMBL359819 0.75 MAPT (0.46) JAK2JAK1TYK2JAK3PIK3CA
SCHEMBL27214416 0.69 PIK3CA (0.59) AKT1PIK3CAMTORMAPK1POLB
SCHEMBL12991818 0.68 LGMN (0.49) JAK2JAK1TYK2JAK3PIK3CA
SCHEMBL359690 0.67 LGMN (0.56) JAK2JAK1TYK2JAK3PIK3CA
SCHEMBL16680612 0.66 DHFR (0.45) JAK2JAK1TYK2JAK3PIK3CA
SCHEMBL823504 0.66 DHFR (0.45) JAK2JAK1TYK2JAK3PIK3CA
SCHEMBL2712015 0.65 LRRK2 (0.48) JAK2JAK1TYK2JAK3MAPK1
SCHEMBL2949706 0.65 PIK3CA (0.57) AKT1PIK3CAMTORPOLBMAPT
SCHEMBL25771640 0.64 MAPT (0.49) MAPK1L3MBTL1SMN1; SMN2MAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130178469-A1 NOVEL ANTIVIRAL AGENTS SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY (SIOC) (CN) 2013-07-11 US disclosed
EP-2593460-A1 7, 9-NITROGEN RADICAL-4-OXO-4H-PYRIDO[L,2-A]PYRIMIDINE-2-CARBOXYLIC ACID BENZYLAMIDE ANTI-VIRALS Avexa Limited (AU) 2013-05-22 EP disclosed
WO-2012006680-A1 7, 9-NITROGEN RADICAL-4-OXO-4H-PYRIDO[L,2-A]PYRIMIDINE-2-CARBOXYLIC ACID BENZYLAMIDE ANTI-VIRALS AVEXA LIMITED (AU) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130178469-A1 NOVEL ANTIVIRAL AGENTS EIF2AK2, IFNAR1, IRF3 JAK2 2095/4885JAK1 388/4885TYK2 3767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.